Skip to main content
. 2023 Feb 21;17(2):e0011129. doi: 10.1371/journal.pntd.0011129

Table 2. Base-case analysis.

Strategy Cost, US$
Incremental cost, US$ Effectiveness, QALYs Incremental QALYs ICER, US$/QALY gained Effectiveness, LYs Incremental LYs ICER, US$/LY gained
No screening 2.18 - 24.94580 - - 24.94807 - -
HTLV-1 antenatal screening 76.85 74.67 24.94766 0.00186 40,100 24.94813 0.00006 1,245,303

HTLV-1, human T cell leukemia virus 1; QALY, quality-adjusted life-year; LY, life expectancy life-year; ICER, incremental cost-effectiveness ratio